PGI2 ADVERSE EVENTS OF PROMETHAZINE AND ONDANSETRON IN YOUNG CHILDREN AND WOMEN OF CHILD-BEARING AGE: A PHARMACOVIGILANCE STUDY BASED ON THE FDA ADVERSE EVENT REPORTING SYSTEM  by Seddoh, SA et al.
Abstracts A69
the warfarin and $10,195 (12,780) in the warfarin and NSAID groups (p < 0.01). 
CONCLUSIONS: This analysis did not identify a difference in the odds of having a 
GI bleed when on warfarin or warfarin plus NSAIDS. Unexpectedly, there were sig-
niﬁcantly lower costs for the warfarin plus NSAIDs group. These results should be 
interpreted with caution due to the small sample size and limitations of retrospective 
analysis.
PGI2
ADVERSE EVENTS OF PROMETHAZINE AND ONDANSETRON IN 
YOUNG CHILDREN AND WOMEN OF CHILD-BEARING AGE: A 
PHARMACOVIGILANCE STUDY BASED ON THE FDA ADVERSE EVENT 
REPORTING SYSTEM
Seddoh SA1, Guo JJ2, Ajayi FO3, Wigle P1
1University of Cincinnati, Cincinnati, OH, USA, 2University of Cincinnati Medical Center, 
Cincinnati, OH, USA, 3Procter & Gamble Company, Mason, OH, USA
OBJECTIVES: Pregnant women may use promethazine or ondansetron for nausea 
and vomiting during pregnancy (NVP). The long-term safety and its potential risks 
on the fetus and newborns are widely unknown. Promethazine has a black boxing 
warning for contraindicating its use in infants and young children. The purpose of 
this study was to quantify and describe adverse events (AEs) related to these two 
medications in child-bearing age women and young children. METHODS: The data 
source was the FDA’s Adverse Events Reporting System database from 1997 to 2006. 
Using a retrospective data analysis, AEs for all patients with study drugs were com-
pared to that for children ages 0–6 years old and women of child-bearing age (CBA) 
15- 50 years old. The annual frequencies of AEs for both study drugs were analyzed 
and stratiﬁed by age group and gender. The related AEs were categorized by clinical 
outcomes, pregnancy outcomes, route of administration, and duration of therapy. 
RESULTS: A total of 392,229 AEs for promethazine and 282,056 AEs for ondanset-
ron were reported. Of those, 13.7% of ondansetron and 22% promethazine AEs were 
for CBA women with the peak for age 35–50; while 13.1% ondansetron and 13.8% 
promethazine AEs were for children age 0–6 with the peak for age 0–2. There were 
23.68% and 13.54% AEs related to promethazine and ondansetron long-term use 
(greater than 90 days) among CBA women, respectively. The most common routes of 
administration were oral and intravenous. For CBA women, the frequent AE preg-
nancy outcomes were maternal complications (26%), premature labor (9%), maternal 
drugs affecting fetus (8%) and spontaneous abortion (4%); while the most frequent 
AEs for children were neonatal respiratory arrest (0.25%) and neonatal apneic attack 
(0.17%). CONCLUSIONS: AEs of promethazine and ondansetron among children 
and CBA women are common. The risk of their off-label use for the long-term treat-
ment of NVP should be recommended with cautions.
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OBJECTIVES: The etiology of functional dyspepsia (FD) is debated. However, no 
published data exist on the associated co-morbid conditions with FD. This study aimed 
to assess the prevalence, services, and costs related to co-morbid conditions associated 
with FD. METHODS: Retrospective database analysis on a 4-year study period, from 
January 1, 2001, through December 31, 2004 using payroll data and adjudicated 
health insurance medical and prescription claims on more than 300,000 employees. 
Study comparisons were performed among employees with FD and propensity-score-
matched employees without FD (controls). Outcome measures included the preva-
lence, costs and utilization of health services for various comorbid conditions as 
deﬁned by the Agency for Healthcare Research and Quality (AHRQ). RESULTS: 
Employees in cohort FD (N = 1669) and a 50:1 matched control-cohort (N = 83,450) 
were compared. Employee with FD were more likely to have all major diagnostic 
categories (MDC) including digestive system, blood and blood forming organs, mental 
disorders, infections and parasitic disease, etc. except pregnancy and prenatal related 
disease, compared to matched controls. The top MDC prevalence ratios between the 
two groups were for digestive systems (6.3:1), blood and blood form organs (2.6:1), 
mental disorders (2.1:1), and infectious & parasitic disease (2.0:1). More interestingly, 
18 of the top 30 most prevalent AHRQ “speciﬁc” categories were non-speciﬁc with 
the terms like “other” or “undeﬁned” in the title. Moreover, annual medical costs for 
the FD cohort were greater than for controls in 155 (59%) of the 261 AHRQ’s Speciﬁc 
Categories and signiﬁcantly greater (P ≤ 0.05) in 76 categories (29%). Similarly, the 
services were greater for 179 (69%) of the 261 Speciﬁc Categories and signiﬁcantly 
greater (P ≤ 0.05) in 110 categories (42%). CONCLUSIONS: Thisstudy showed excess 
comorbidity in employees with FD compared to employees without FD, might be a 
major determinant factors for excess health-care services and health-care costs of 
functional dyspepsia.
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OBJECTIVES: Hepatitis C affects approximately 180 million people worldwide. It is 
one of the main causes of liver disease and is the predominant etiology for liver 
transplantation. This study performs a systematic review and meta-analysis of pub-
lished randomized controlled trials comparing efﬁcacy of peginterferon-alpha-2a 
versus peginterferon-alpha-2b both in association with ribavirin in order to assess 
which is more effective in the treatment of HCV infection. METHODS: A thorough 
search in MEDLINE, Lilacs, Cochrane library and Embase databases was conducted 
in the last quarter of 2009. Manual searches in specialized websites were also carried 
out. Included studies were those which evaluate treatment efﬁcacy of peginterferon 
alpha-2a versus peginterferon alpha-2b both plus ribavirin for hepatitis C treatment 
in naïve patients or nonresponders to other therapies not co-infected with HIV. 
According to heterogeneity test, a ﬁxed or a random-effect models was adopted for 
meta-analysis. RESULTS: A total of 570 citations (databases citation without dupli-
cates plus manual searches) were found but only seven met the inclusion criteria: 1) 
Ascione, 2009; 2) Rumi, 2009; 3) McHutchison, 2009; 4) Yenice, 2006; 5) Scotto, 
2008; 6) Kolakowska, 2008; 7) Berak, 2007. All studies are randomized controlled 
trials. Overall, peginterferon-alpha-2a has shown higher sustained virological response 
(SVR) as compared to peginterferon-alpha-2b: 51.7% versus 42.4% (RR = 1.23, IC 
95% 1.10 – 1.38, assuming a ﬁxed-effect model). For genotypes 1/4: 42.1% versus 
33.3% (RR = 1.11, IC 95% 1.02 – 1.20, assuming a ﬁxed-effect model) and for geno-
types 2/3: 79.2% versus 73.8% (RR = 1.11, IC 95% 1.01 – 1.22, assuming a ﬁxed-
effect model). CONCLUSIONS: These ﬁndings suggest that peginterferon-alpha-2a is 
associated with a higher clinical response than peginterferon-alpha-2b indicating that 
it should be used as the standard-of-care therapy. Our results are in line with another 
recent published systematic review (Awad, 2009) which concluded that peginterferon-
alpha-2a has a higher SVR as compared to peginterferon-alpha-2b, with similar safety 
proﬁle.
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OBJECTIVES: To investigate whether the 5-HT3 receptor antagonists—ondansetron, 
granisetron, tropisetron, and dolasetron—used for the prevention of post-operative 
nausea and vomiting (PONV) differ in efﬁcacy. METHODS: A meta-analysis was 
conducted using published studies. A systematic literature search within Pubmed and 
the Cochrane Library for randomized, controlled, double-blinded studies measuring 
efﬁcacy in terms of PONV prophylaxis was conducted. The odds of patients exempted 
from PONV and post-operative vomiting (POV) within each study arm 24 hours after 
surgery were the primary indices of drug efﬁcacy. Indirect comparisons using random 
effect models were conducted. Subgroup analyses excluding controversial studies and 
controlling amount of dose and administration route were also conducted. RESULTS: 
A total of 82 studies were identiﬁed, representing 15,709 patients. In terms of prevent-
ing PONV, the analysis indicated that granisetron was statistically signiﬁcantly better 
than ondansetron (odds ratio(OR) = 1.46, 95% conﬁdence interval(CI):1.08–2.00) 
and dolasetron(OR = 1.56, 95%CI: 1.03–2.34); no other statistically signiﬁcant rela-
tionships comparing either two of the four drugs were found. In terms of preventing 
POV, the four antiemetic drugs had comparable efﬁcacy: granisetron showed similar 
efﬁcacy as compared to ondansetron(OR = 1.61, 95%CI: 0.99–2.63), tropisetron(OR 
= 1.70, 95%CI: 0.95–3.05) and dolasetron(OR = 1.35, 95%CI: 0.78–2.27); ondanset-
ron exhibited comparable efﬁcacy as compared to tropisetron(OR = 1.06, 95%CI: 
0.63–1.79) and dolasetron(OR = 0.84, 95%CI = 0.52–1.31); tropisetron and dolas-
etron were also similar in efﬁcacy(OR = 0.80, 95%CI = 0.44–1.37). Subgroup analyses 
also found that the four drugs did not differ in efﬁcacy. All 5-HT3 receptor antagonists 
were statistically signiﬁcantly better than placebo. CONCLUSIONS: With respect to 
PONV prophylaxis, granisetron was statistically signiﬁcantly better than ondansetron 
and dolasetron; ondansetron, tropisetron, and dolasetron exhibit similar efﬁcacy. With 
respect to POV prophylaxis, ondansetron, granisetron, tropisetron, and dolasetron 
appeared to have comparable efﬁcacy.
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OBJECTIVES: Research has suggested that admissions for diverticular disease (DD) 
are on the rise in Western countries, particularly among a younger patient population. 
However, relatively little is known about how this increase has impacted the use of 
surgical procedures for the management of DD. The goals of this study were a) to 
determine temporal trends in the use of surgical procedures (laparoscopic colectomy 
[LC] and open colectomy [OC]) for DD, and b) to investigate temporal changes in 
